NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

胎盤成長因子:開發中產品分析

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drugs In Development, 2021

出版商 Global Markets Direct 商品編碼 398837
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
胎盤成長因子:開發中產品分析 Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drugs In Development, 2021
出版日期: 2021年08月31日內容資訊: 英文 113 Pages
簡介

本報告提供以胎盤成長因子為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

胎盤成長因子 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Alteogen Inc.
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Clearside BioMedical, Inc.
  • Formycon AG
  • Regeneron Pharmaceuticals Inc
  • ThromboGenics NV

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2939TDB

Summary:

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 29 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 12, 2, 2, 6, 6 and 1 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Central Retinal Vein Occlusion, Choroidal Neovascularization, Metastatic Colorectal Cancer, Retinal Vein Occlusion, Retinopathy, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Colorectal Cancer, Corneal Neovascularization, Graves' Ophthalmopathy, Macular Degeneration, Medulloblastoma, Myopia, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinoblastoma, Retinopathy Of Prematurity, Solid Tumor and Uveal Melanoma.

The latest report Placenta Growth Factor - Drugs In Development, 2021, outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
  • The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

  • Introduction
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
  • Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Alteogen Inc, 2021
  • Pipeline by Amgen Inc, 2021
  • Pipeline by Celltrion Inc, 2021
  • Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2021
  • Pipeline by Cinnagen Co, 2021
  • Pipeline by Clover Biopharmaceuticals, 2021
  • Pipeline by Formycon AG, 2021
  • Pipeline by GlycoNex Inc, 2021
  • Pipeline by Hexal AG, 2021
  • Pipeline by Huons Global Co Ltd, 2021
  • Pipeline by i2 Pharmaceuticals Inc, 2021
  • Pipeline by Johnson & Johnson, 2021
  • Pipeline by Kidswell Bio Corp, 2021
  • Pipeline by Lupin Ltd, 2021
  • Pipeline by Luye Pharma Group Ltd, 2021
  • Pipeline by Oncosimis Biotech Pvt Ltd, 2021
  • Pipeline by Oxurion NV, 2021
  • Pipeline by Panolos Bioscience, 2021
  • Pipeline by PharmAbcine Inc, 2021
  • Pipeline by Prestige BioPharma Ltd, 2021
  • Pipeline by Regeneron Pharmaceuticals Inc, 2021
  • Pipeline by Rophibio Inc, 2021
  • Pipeline by Sam Chun Dang Pharm Co Ltd, 2021
  • Pipeline by Samsung Bioepis Co Ltd, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021